Manganese superoxide dismutase (MnSOD) catalyzes the dismutation of a specific type of reactive oxygen species, superoxide radicals, into hydrogen peroxide and oxygen (1) . Accumulation of reactive oxygen species can damage DNA, proteins, and lipids, leading to the initiation or promotion of cancer (2, 3) . MnSOD, the only known superoxide scavenger in mitochondria, may be particularly important for antioxidant defense because mitochondria are the major sites for cellular metabolism and hence production of reactive oxygen species (4) .
The signal sequence is essential for correct transport and processing of proteins by mitochondria (5). Indirect evidence suggests that the alanine-to-valine polymorphism at codon 16 (Ala16Val) in the signal sequence of MnSOD (5), also described as the -9 position (6), produces a conformational change in the helical structure of the protein. This change may decrease the efficiency of transport into mitochondria for the Val isoform of the protein (6,7), although other studies (8,9) support alternate and opposing functional effects of this polymorphism. The Ala16Val MnSOD polymorphism is common among Caucasians [with a frequency of 41%-55% (8- 11) ].
In the present study, we evaluated the association of the common Ala16Val MnSOD polymorphism with the overall risk of lung cancer in a large Caucasian population. We hypothesized that individuals with the Val allele, associated with less efficient MnSOD enzyme transport into the mitochondria, have an increased susceptibility to lung cancer because of the more rapid accumulation of cancer-causing reactive oxygen species.
As part of an ongoing, hospitalbased, lung cancer case-control study initiated in 1992 at the Massachusetts General Hospital, Boston, MA, 2783 participants were enrolled as of September 2000. The study was approved by the Institutional Review Board at both the Massachusetts General Hospital and the Harvard School of Public Health, Boston, MA.
1 This study population has been described in detail previously (12) (13) (14) (15) (16) . DNA was available, and the Mn-SOD polymorphism was genotyped successfully for 2560 (92%) participants. 2 Demographic characteristics for those with genotype data were similar to those of the entire study population.
A modified version of the standardized American Thoracic Society respiratory questionnaire (17) was administered by a trained research nurse, who obtained information on demographics, medical and family cancer histories, and detailed smoking and work histories (12) (13) (14) (15) (16) . Peripheral blood specimens were collected for all participants.
To reduce potential variation in allele frequency by ethnicity, we analyzed only Caucasians (93% of our genotyped study population) with complete information on sex, age, and smoking variables (smoking status, pack-years, and years after smoking cessation). The study population consisted of 1101 case patients and 1239 control subjects. Formal tests of statistical interaction were conducted by use of the likelihood ratio test comparing nested models with and without the interaction terms of interest. All statistical tests were two-sided.
Population differences between case patients and control subjects reflect typical risk factors for lung cancer (Table 1) . Compared with control subjects, case patients were more likely to be older, male, and current smokers and to have a higher cumulative exposure to tobacco smoke and a family history of lung cancer but were less likely to be college graduates.
Among control subjects, the frequency distribution of the MnSOD genotype was in Hardy-Weinberg equilibrium ( 2 goodness of fit, P ‫ס‬ .89). This variant Val allele frequency of 48.6% was comparable to the frequency reported in another U.S. Caucasian population (8). The genotype distribution in our study was statistically significantly different between case patients and control subjects, where Val/Val was observed in more case patients and Ala/Ala was observed in more control subjects (Pearson 2 , P ‫ס‬ .02). Given that multiple comparisons in subgroups may have led to chance findings, further evaluation of possible effect modification by smoking is needed. Our findings of an increased risk of lung cancer associated with the Val allele (corresponding to the lower efficiency of MnSOD transport into mitochondria) may be explained by decreased removal of reactive oxygen species. This increased risk results from the accumulation of cell damage. MnSOD plays a key role in cell survival by providing resistance to oxidative injury after exposure to adverse conditions, such as exposure to radiation (18, 19) . Studies (20) (21) (22) 
In addition, MnSOD may have tumor suppressor activity. Studies that induced overexpression of MnSOD in a variety of tumor or transformed cell lines (23) (24) (25) (26) (27) found suppressed growth rates and plating efficiency, increased morphologic differentiation, and decreased tumor formation in mice. Less efficient underlying MnSOD activity conferred by the Val allele may be associated with decreased tumor suppressor activity and increased cancer risk. However, MnSOD expression may also be negatively regulated by tumor suppressor p53 (18) , and further evaluation of the biologic mechanisms for MnSOD and the Val isoform in carcinogenesis is needed.
In contrast to our results, the two previously published cancer studies evaluating this polymorphism (8,9) found a statistically significantly increased risk of breast cancer associated with the Ala allele. A U.S. study (8) found that risk in premenopausal women with the Ala/Ala genotype was four times greater than that in women with the Val/Val genotype. A Finnish study (9) , however, observed a statistically significant association for the Ala allele mainly in postmenopausal women (OR ‫ס‬ 1.7; 95% CI ‫ס‬ 1.2 to 2.5). These differences between lung and breast cancer associations with MnSOD genotype suggest that the role of MnSOD in carcinogenesis may vary for different populations and different tumors (8, [28] [29] [30] [31] [32] [33] .
Although we did not use populationbased control subjects, allele frequen- 2 or t test. All statistical tests were two-sided. †Presented as mean ± standard deviation. ‡Presented as number (%). §150 individuals had missing information on education, and 248 had missing information on family history of lung cancer.
Pack-years (a measure of cumulative smoking exposure) was defined as the average number of packs of cigarettes smoked per day multiplied by the number of years of smoking.
¶Based on dataset with 1083 case patients and 1239 control subjects, where 18 case subjects were removed from the original dataset because their histologic type or stage was considered to be ineligible. In addition, 27 case patients had missing information on histologic type and 43 case patients had missing information on stage.
նIncludes individuals with large cell (n ‫ס‬ 83), small cell (n ‫ס‬ 92), mixed histologic subtype (n ‫ס‬ 26), and carcinoid (n ‫ס‬ 19) and individuals with more than one primary lung tumor (n ‫ס‬ 21). Nineteen case patients were classified as unknown.
cies were representative of those in the general Caucasian population. As discussed in our previous reports (12) (13) (14) (15) (16) , it is unlikely that our selection of control subjects (i.e., spouses or friends) is related to genotype. These results, however, may not be applicable to non-Caucasian populations. Although control subjects were not matched at enrollment on risk factors (e.g., age and sex), we controlled for important risk factors in our analysis by including them in adjusted models or stratifying on these covariates.
In conclusion, we found statistically significantly increased risks of lung cancer for individuals heterozygous (OR adj ‫ס‬ 1.34; 95% CI ‫ס‬ 1.05 to 1.70) or homozygous (OR adj ‫ס‬ 1.67; 95% CI *Logistic regression was performed to calculate the OR (95% CI). †Adjusting for age, sex, smoking status, square root of pack-years, and years after smoking cessation where appropriate. Variables were modeled as follows: sex, age (years), smoking status (never, current, or ex-smoker), time after smoking cessation (years), and the square root of pack-years. Based on previous studies in this population (16) , the square root transformation of pack-years was more linearly related to the log odds of lung cancer than untransformed pack-years; therefore, we used the square root of pack-years in our models.
‡Wald test for trend (P<.001). All statistical tests were two-sided. §(% case patients : % control subjects). Because the average age at diagnosis for lung cancer patients in the United States is 60 years (37), lung cancer case patients aged 55 years or younger were considered to be an appropriate group of younger aged patients.
¶Where the outcome is histologic type versus all control subjects. նWhere the outcome is stage versus all control subjects.
NOTES

1
Eligible case patients were individuals 18 years or older who were seen at the Massachusetts General Hospital in the Thoracic Surgery or Hematology-Oncology Units for newly diagnosed primary lung cancer. Enrollment was restricted initially to individuals with operable lung cancer, but the case definition was expanded to include patients with inoperable lung cancer after August 1996. Histologic confirmation of all case diagnoses was determined by a lung pathologist. Control subjects were healthy friends or spouses of either lung cancer or cardiothoracic patients, with no specific matching characteristics. Written informed consent was obtained for all subjects at the time of enrollment. . There was 100% agreement (in 60 randomly chosen samples) between this method and a previously reported PCR-restriction fragment length polymorphism method using an AluI restriction enzyme (36) with a modified reverse primer (5Ј-GAAGCGAGTTCTCCTCCACG-GAG-3Ј).
